Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 17, 2017
Pharmacy Choice - Pharmaceutical News - Mylan releases generic version of Trilafon - November 17, 2017

Pharmacy News Article

 4/21/17 - Mylan releases generic version of Trilafon

CANONSBURG ? Mylan N.V. announced Thursday the U.S. launch of Perphenazine Tablets USP, in 2-, 4-, 8- and 16- mg doses, a generic version of the reference listed drug, Trilafon tablets, originally marketed by Schering. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is used in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults.Perphenazine tablets had U.S. sales of approximately $41 million for the 12 months ending Feb. 28, according to IMS Health.



© Copyright, 2017, Observer Publishing Company of Washington, Pa.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Nov 17: Adverse Drug Events: Risk Reduction & Documentation
Last Chance
Nov 19: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415